Phosphorylated tau in plasma could be a biomarker of lower motor neuron impairment in amyotrophic lateral sclerosis.
暂无分享,去创建一个
A. Priori | S. Messina | N. Ticozzi | F. Verde | A. Ratti | V. Silani | L. Maderna | B. Poletti | C. Morelli | E. Torresani | C. Colombrita | A. Dubini | Silvia Torre | E. Colombo | Alessio Maranzano | Francesco Gentile | Ilaria Milone | Alberto Doretti
[1] P. Avoni,et al. Elevated plasma p-tau181 levels unrelated to Alzheimer’s disease pathology in amyotrophic lateral sclerosis , 2023, Journal of Neurology, Neurosurgery, and Psychiatry.
[2] S. Messina,et al. Phenotypic correlates of serum neurofilament light chain levels in amyotrophic lateral sclerosis , 2023, Frontiers in Aging Neuroscience.
[3] A. Nairn,et al. Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer’s disease , 2022, Alzheimer's Research & Therapy.
[4] S. Corti,et al. Correlation between clinical phenotype and electromyographic parameters in amyotrophic lateral sclerosis , 2022, Journal of Neurology.
[5] J. Trojanowski,et al. Elevated Plasma Phosphorylated Tau 181 in Amyotrophic Lateral Sclerosis , 2022, Annals of neurology.
[6] N. Dahodwala,et al. Reliable and efficient scale to assess upper motor neuron disease burden in amyotrophic lateral sclerosis , 2019, Muscle & nerve.
[7] T. Hortobágyi,et al. Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria , 2017, Amyotrophic lateral sclerosis & frontotemporal degeneration.
[8] F. Madotto,et al. The validation of the Italian Edinburgh Cognitive and Behavioural ALS Screen (ECAS) , 2016, Amyotrophic lateral sclerosis & frontotemporal degeneration.
[9] A. Al-Chalabi,et al. A proposed staging system for amyotrophic lateral sclerosis , 2012, Brain : a journal of neurology.
[10] C. Schmid,et al. A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.